SOURCE: Theravance

June 27, 2005 20:44 ET

Theravance to Webcast Annual Stockholders' Meeting on June 30, 2005

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- June 27, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its Annual Stockholders' Meeting on Thursday, June 30, 2005, which meeting will include an update on the operations of the company by Rick E Winningham, the Chief Executive Officer of Theravance.

An accompanying listen-only conference call will be available at 4:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial 800-238-9007 from the U.S., or 719-457-2622 for international callers. Those interested in listening to the audio feed live via the Internet may do so by visiting the company's web site at www.theravance.com. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the annual stockholders' meeting will be available on the company's web site for 30 days through July 29, 2005. A telephone replay will also be available from 8:00 p.m. through 11:59 p.m. Eastern Daylight Time, July 11 by dialing 800-238-9007 from the U.S., or 719-457-0820 for international callers, and entering confirmation code 9174885.

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Of the six programs in development, two are in late stage -- telavancin and the Beyond Advair collaboration with GlaxoSmithKline. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal motility disorders. By leveraging its proprietary insight of multivalency to drug discovery focused on validated targets, Theravance is pursuing a next generation drug discovery strategy designed to discover superior medicines in large markets. For more information, please visit the company's web site at www.theravance.com.

NOTE: THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

This press release contains and statements made during the annual stockholders' meeting will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Examples of such statements include statements relating to the goals and expected results of clinical and preclinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates and the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights. These statements are and will be based on the current estimates and assumptions of the management of Theravance as of the date of this press release and the annual stockholders' meeting, respectively, are naturally subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing or completing clinical and preclinical studies, the potential that results of clinical or preclinical studies indicate product candidates are unsafe, ineffective, inferior or not superior, and delays or failure to achieve regulatory approvals. These and other risks are described in greater detail under the heading "Factors Affecting Results, Including Risks and Uncertainties" contained in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2005 and the risks discussed in our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.

Contact Information

  • Contact Information:

    Investors
    Theravance, Inc.
    Greg Sturmer
    Vice President, Finance and Investor Relations
    650-808-4100
    Email Contact

    Media
    Theravance, Inc.
    David Brinkley
    Senior Vice President, Commercial Development
    650-808-3784
    Email Contact